Supernus Pharmaceuticals | SUPN - Operating Profit


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Supernus Pharmaceuticals

Supernus Pharmaceuticals reported $5.18M in Operating Profit for its fiscal quarter ending in March of 2023.


Operating Profit Change
Abbott ABT:US USD 1.51B 205M
ANI Pharmaceuticals ANIP:US USD 9.9M 8.07M
Bristol-Myers Squibb BMY:US USD 3.1B 1.15B
Cara Therapeutics CARA:US USD -27650000 3.66M
Corcept Therapeutics CORT:US USD 14.85M 7.65M
Eisai 4523:JP JPY 26.22B 17.65B
Eli Lilly LLY:US USD 1.49B 342.4M
Endo International ENDP:US USD 3.46M 240.32M
Horizon Pharma HZNP:US USD 35.99M 137.94M
Marinus Pharmaceuticals MRNS:US USD -32963000 2.95M
Pacira PCRX:US USD -20017000 10.12M
Perrigo PRGO:US USD 48.5M 17.5M
Pfizer PFE:US USD 6.79B 1.62B
Revance Therapeutics RVNC:US USD -58032000 86.38M
Supernus Pharmaceuticals SUPN:US USD 5.18M 29.16M
United Therapeutics UTHR:US USD 284.4M 108.8M